Apic Bio Leadership

Biopharma executive with experience in building early-stage companies. Proven track record of closing partnerships with industry leading companies. Long-term, strategic and independent thinker.

Specialties: Licensing and Business Development

Non-dilutive Financing

Strategic Planning

Finance

Patent and Product Portfolio Management

Start-up Operations

Commercial Partnerships

Strategic Market Development

Scott Loiler is a Chief Technology Officer at Apic Bio Inc. He has worked as Scientific Director at Vector Development.

Daniel Geffken has served as a member of the Windtree Board of Directors since April 2019. He serves as Chairman of the Board’s Audit Committee and is a member of the Compensation Committee. Mr. Geffken has more than 30 years of financial management experience to the board, ranging from start-ups to publicly traded companies with over $1 billion market capitalizations. Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has also served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Directors of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra. Since 2013, he has assisted in ten initial public offering filings. Over the course of his career, he has assisted in raising more than $1 billion in equity and debt securities for life science companies.

Daniel holds a BS from The Wharton School, University of Pennsylvania, and an MBA from Harvard Business School.

Biopharmaceutical executive jointly responsible for overall business and corporate strategy. Fifteen+ years of scientific, clinical and regulatory experience. Implemented strategy and lead cost-effective programs including rare/orphan disorders from early clinical development (IND filings and proof of concept studies) through registrational studies (NDA and sNDA) for both small molecules and gene therapy.

Biopharma executive with experience in building early-stage companies. Proven track record of closing partnerships with industry leading companies. Long-term, strategic and independent thinker.

Specialties: Licensing and Business Development

Non-dilutive Financing

Strategic Planning

Finance

Patent and Product Portfolio Management

Start-up Operations

Commercial Partnerships

Strategic Market Development

Biopharma executive with experience in building early-stage companies. Proven track record of closing partnerships with industry leading companies. Long-term, strategic and independent thinker.

Specialties: Licensing and Business Development

Non-dilutive Financing

Strategic Planning

Finance

Patent and Product Portfolio Management

Start-up Operations

Commercial Partnerships

Strategic Market Development